Global Endovascular Robot System Market Outlook
Revenue, 2024
$1.1B
Forecast, 2034
$3.9B
CAGR, 2025 - 2034
13.9%
The Endovascular Robot System industry revenue is expected to be around $1.2 billion in 2025 and expected to showcase growth with 13.9% CAGR between 2025 and 2034. The Endovascular Robot System market continues its growth path because healthcare providers want precise and consistent procedures with reduced radiation exposure during complex vascular procedures. The market shows rapid growth because tertiary hospitals, hybrid operating rooms adopt the technology as healthcare moves toward minimally invasive procedures and cardiovascular and neurovascular cases increase and staff shortages persist. The market confidence grows stronger because of vendor pipelines and imaging integration, improving reimbursement while health systems focus on throughput and standardized outcomes, data driven quality which supports continued investment and multi site deployments.
The Endovascular Robot System integrates physician console functionality with robotic drive capabilities and catheter/guidewire control modules and 3D imaging and haptic feedback and force sensing for precise remote navigation. The system operates for coronary PCI procedures and peripheral artery interventions and neurovascular stroke therapies and aortic aneurysm repair. The current market shows AI assisted planning and dose optimization and angiography suite integration and smaller footprint designs and single use disposables which enhance workflow efficiency.
Market Key Insights
- The Endovascular Robot System market is projected to grow from $1.1 billion in 2024 to $3.9 billion in 2034. This represents a CAGR of 13.9%, reflecting rising demand across Percutaneous Coronary Intervention (PCI) and Peripheral Vascular Interventions (PVI).
- The market exhibits an oligopolistic structure with only 6 prominent players, with Siemens Healthineers and Robocath commanding the largest shares.
- U.S. and China are the top markets within the Endovascular Robot System market and are expected to observe the growth CAGR of 12.5% to 16.7% between 2024 and 2030.
- Emerging markets including India, Brazil and Turkey are expected to observe highest growth with CAGR ranging between 9.7% to 14.6%.
- Slow adoption of 5G Enabled Teleoperated Vascular Care transition within key players in Endovascular Robot System market is creating a revenue window for adjacent and alternate markets like Magnetic catheter navigation systems and to improve its use-case penetration in Pci and Pvi applications and expected to capture $167 million revenue from existing Endovascular Robot System market.
- The Endovascular Robot System market is set to add $2.8 billion between 2024 and 2034, with industry players targeting Pvi & Neurovascular intervention Applications projected to gain a larger market share.
- With Rising demand for minimally invasive procedures, and Need to reduce radiation exposure., Endovascular Robot System market to expand 267% between 2024 and 2034.
Opportunities in the Endovascular Robot System
GCC private hospital groups are also building hybrid OR and cath lab facilities to draw medical tourists and high end cardiovascular patients. Robotic PCI provides sub millimeter precision and reduced radiation and marketing differentiation for complex CTO and multivessel cases. The market for coronary endovascular robot systems will expand the most because of turnkey EPC partnerships and managed service agreements and payer collaboration for bundled payments and cross border Centers of Excellence networks that connect flagship hubs.
Growth Opportunities in North America and Asia-Pacific
The North American endovascular robot system market advances because of high procedure numbers in neurovascular and structural heart programs and FDA clearance of portfolios and favorable reimbursement for complex PCI and peripheral interventions. The market opportunities exist in comprehensive stroke centers and IDNs that want to reduce radiation exposure and achieve precise navigation and remote robotic capabilities to handle staffing shortages. The market leadership belongs to Siemens Healthineers and niche innovators who use hospital GPO contracts and imaging integration partnerships to determine market share. The market will expand because of capital expenditure cycles and AI navigation systems and outcome data that demonstrates robotics shortens fluoroscopy time and enhances operational efficiency.
The Asia Pacific endovascular robot system market experiences rapid growth because of increasing cardiovascular and cerebrovascular diseases and expanding catheterization labs and government support for digital health initiatives. The market presents three main opportunities which include China and India localization and distributor access to tier 2 hospitals and cost optimized platforms that match tender procurement and value based care models. The market competition consists of multinational companies alongside agile domestic OEMs which differentiate themselves through NMPA/PMDA approvals and KOL led trials and imaging robot integration. The path to success depends on joint venture manufacturing operations and local stent and guidewire compatibility and scalable training programs and teleproctoring services that will drive neurointervention adoption despite payment and capital expenditure limitations.
Market Dynamics and Supply Chain
01
Driver: Rising incidence of complex vascular disease and shortage of specialist interventionalists accelerate endovascular robot system adoption
The increasing prevalence of atherosclerotic and neurovascular disease also stems from global aging and diabetes and hypertension which results in more complex lesions that require minimally invasive treatment. Hospitals need robotic platforms to achieve precision navigation and catheter stability and reduce radiation exposure because of challenging anatomies and extended fluoroscopy times and distant target locations. The limited number of neurointerventionalists and endovascular specialists who work outside urban areas restricts patients from receiving timely medical care. Teleproctoring systems together with potential telerobotics and standardized workflows help extend expert reach and maintain consistency in medical care. The neurovascular application market will also experience its fastest growth through robotic assisted mechanical thrombectomy and aneurysm embolization procedures. Stroke networks and hub and spoke models increase the need for scalable and reproducible intervention capabilities.
The combination of AI enabled vessel segmentation with path planning and motion compensation technologies enables semi autonomous operations and precise torque management and automated wire transfer capabilities. The integration of OCT/IVUS and 3D angiography roadmaps with robots enables both reduced fluoroscopy time and contrast use and enhanced crossing success in difficult lesion procedures. The decision support and automation modules enhance procedural efficiency and reproducibility which strengthens the clinical and economic case for adoption. The most significant immediate benefit will also occur in complex coronary PCICTO crossings and bifurcation stenting procedures that operate in high volume cath labs which aim to achieve consistent results.
02
Restraint: High total cost of ownership and uncertain reimbursement
The adoption of endovascular robot systems faces barriers because of high initial costs and service agreements and proprietary single use disposables that reduce hospital profitability and make value analysis approvals more difficult especially in interventional cardiology and neurovascular service lines. The uncertain nature of reimbursement payments combined with unclear payment increments for robotic endovascular procedures creates challenges for ROI calculations which leads to longer procurement times and focuses demand on well funded tertiary centers while community hospitals and ASCs choose conventional catheter based interventions. The price sensitivity drives customers toward leasing and pay per use models which decreases average selling prices and reduces installed base growth and consumable pull through while slowing down market velocity and vendor revenue scalability.
03
Opportunity: Peripheral arterial disease interventions in U.S. community hospitals driving Endovascular Robot System adoption and Neurovascular stroke thrombectomy programs in India and Southeast Asia advancing Endovascular Robot System uptake
Community and rural hospitals experience three major challenges which include insufficient interventional staff, radiation safety restrictions and increasing peripheral vascular disease cases. Robotic assisted angioplasty with intravascular navigation enables hospitals to expand their case mix without requiring permanent specialist staff while providing nighttime coverage and enhancing operator comfort. The peripheral vascular robot system market will experience its fastest expansion through femoropopliteal and below the knee lesion procedures because of GPO contracts and leasing models and telerobotic proctoring partnerships with academic vascular centers.
The worlds highest stroke burden exists in India and Southeast Asia but there are not only enough thrombectomy capable centers available. Public tertiary networks require scalable neurointervention capacity together with standardized quality and radiation dose reduction. The combination of endovascular robotics with microcatheter automation and AI guided roadmap alignment allows for accelerated training and remote mentorship. The neurovascular robot platform will experience the fastest regional growth because of government tenders and local distributor alliances and outcomes linked procurement criteria.
04
Challenge: Clinical integration barriers and evidence gap
The steep learning curve, proctoring requirements, and workflow disruption in the angiography suite slow clinician adoption, while device compatibility constraints and IT integration needs hinder seamless catheter navigation across diverse cases. The lack of extensive clinical and health economic data showing better results and reduced radiation exposure and shorter procedure times compared to manual methods prevents payers from supporting robotic systems and clinicians from feeling confident in their use which leads hospitals to choose next generation fluoroscopy, IVUS/OCT, or image guided software upgrades instead. The uneven utilization rates and limited procedure indications restrict system use to specific cases which results in reduced consumables demand and creates fragmented market dynamics that slow down the diffusion curve across interventional cardiology, peripheral vascular, and neurointerventional settings.
Supply Chain Landscape
1
Components & Materials
MaxonHamamatsu PhotonicsTerumo
2
Imaging & Navigation Platforms
Siemens HealthineersGE HealthCarePhilips
3
Robot OEMs
CorindusRobocathStereotaxis
4
End Users
Interventional cardiologyNeurovascular interventionPeripheral vascular intervention
1
Components & Materials
MaxonHamamatsu PhotonicsTerumo
2
Imaging & Navigation Platforms
Siemens HealthineersGE HealthCarePhilips
3
Robot OEMs
CorindusRobocathStereotaxis
4
End Users
Interventional cardiologyNeurovascular interventionPeripheral vascular intervention
Use Cases of Endovascular Robot System in Percutaneous Coronary Intervention (PCI) & Peripheral Vascular Interventions (PVI)
Percutaneous Coronary Intervention (PCI) : The robotic assisted PCI procedure employs bedside cassette based drive systems which operate guidewires and balloon/stent catheters through systems like Siemens Healthineers Corindus CorPath GRX and Robocath R One. The shielded cockpit allows operators to perform telemanipulation of devices which enables them to cross lesions and deliver stents and optimize angioplasty procedures. The system provides sub millimeter precision while minimizing radiation and contrast exposure and enhancing procedural ergonomics through consistent results. The largest installed base and strong clinical evidence belong to Siemens while Robocath expands its presence in Europe and Asia through its compact and cost efficient platform.
Peripheral Vascular Interventions (PVI) : The same catheter/guidewire drive medical robotic systems used for iliac, renal, and femoropopliteal lesions perform peripheral vascular interventions to enable precise ballooning, atherectomy support, and stent graft placement. The teleoperated control system provides better stability in complex anatomy and reduces both operator radiation exposure and orthopedic strain while enhancing device accuracy. Siemens Healthineers maintains top regulatory approvals and reference facilities for peripheral indications while Hansen Medical Magellan demonstrated multi directional steerability in its legacy system and Robocath continues to develop PVI clinical programs through hospital partnership growth.
Recent Developments
Endovascular robot systems advance through imaging integrated platforms and AI navigation and 5G telerobotics pilots to reduce radiation exposure and enhance precision. The development of ecosystems and accelerated approval processes results from OEMs and catheter makers and hospitals working together through strategic M&A and funding initiatives. The market participants now focus on neurovascular and peripheral care applications after their initial success with robotic PCI systems.
June 2024 : The first U.S. procedures using the FDA cleared MAGiC catheter on the Genesis RMN robotic navigation system have been completed by Stereotaxis which has led to increased clinical adoption of endovascular robotics.
April 2024 : Robocath secures 40 million financing to accelerate its neurovascular robotic platform development and scale commercialization with MicroPort in China.
December 2023 : Cathbot receives NMPA approval for the R One robotic assisted PCI system, enabling initial commercial launch in China.
Impact of Industry Transitions on the Endovascular Robot System Market
As a core segment of the Medical Device industry,
the Endovascular Robot System market develops in line with broader industry shifts.
Over recent years, transitions such as 5G Enabled Teleoperated Vascular Care and Data Centric, Interoperable Cath Labs have redefined priorities
across the Medical Device sector,
influencing how the Endovascular Robot System market evolves in terms of demand, applications and competitive dynamics.
These transitions highlight the structural changes shaping long-term growth opportunities.
01
5G Enabled Teleoperated Vascular Care
Endovascular robot systems now perform teleoperated surgery by integrating robotic catheter navigation with AI guided imaging and low latency 5G connectivity to enable remote interventions that deliver higher precision and lower radiation exposure and reproducible outcomes. The technological advancement enables stroke thrombectomy and peripheral artery disease care to reach underserved areas while maximizing procedural efficiency and staffing capabilities in hybrid ORs. A regional stroke network demonstrates the FDA clearance of robotic thrombectomy technology at its hub hospital to reduce door to reperfusion times and transfer expenses while establishing new reimbursement methods for telehealth based interventional cardiology and radiology. The model drives cybersecurity enhancements and payer coverage trials and medical liability standards which attract telecom companies and cloud providers and malpractice insurance organizations. This industry transition is expected to add $167 million in the industry revenue between 2024 and 2030.
02
Data Centric, Interoperable Cath Labs
The evolution of robots creates standardized workflows through EHR integration and imaging interoperability and force feedback haptics and analytics that reduce contrast usage and increase throughput. A health system integrates a vendor agnostic robot with fluoroscopy and intravascular imaging under outcome based contracts while using digital twin training to reduce learning curves for structural heart interventions and obtain CE Mark indications which streamlines OEM partnerships and supply chains.